PCVX Vaxcyte Inc

Price (delayed)

$48.755

Market cap

$7.04B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.88

Enterprise value

$6.9B

?
Relative Growth: Rel. Growth: 0
Relative Strength: Rel. Strength: 56
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 5

Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious ...

Highlights
Vaxcyte's equity has increased by 12% QoQ but it has decreased by 6% YoY
The net income has plunged by 86% YoY and by 23% from the previous quarter
The EPS has plunged by 72% YoY and by 22% from the previous quarter

Key stats

What are the main financial stats of PCVX

PCVX stock price

How has the Vaxcyte stock price performed over time
Intraday
3.89%
1 week
-4.51%
1 month
-16.64%
1 year
44.08%
YTD
5.67%
QTD
-16.1%

Financial performance

How have Vaxcyte's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$1.09B
Net income
-$946.53M
Gross margin
N/A
Net margin
N/A
The net income has plunged by 86% YoY and by 23% from the previous quarter
Vaxcyte's operating income has shrunk by 71% YoY and by 18% QoQ

Price vs fundamentals

How does PCVX's price correlate with its fundamentals

Growth

What is Vaxcyte's growth rate over time

Valuation

What is Vaxcyte stock price valuation
P/E
N/A
P/B
2.34
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has plunged by 72% YoY and by 22% from the previous quarter
The P/B is 32% lower than the 5-year quarterly average of 3.3 but 13% higher than the last 4 quarters average of 2.0
Vaxcyte's equity has increased by 12% QoQ but it has decreased by 6% YoY

Efficiency

How efficient is Vaxcyte business performance
Vaxcyte's return on equity has shrunk by 90% YoY and by 25% QoQ
PCVX's ROA has shrunk by 81% YoY and by 24% QoQ
PCVX's ROIC has dropped by 63% year-on-year and by 24% since the previous quarter

Dividends

What is PCVX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PCVX.

Financial health

How did Vaxcyte financials performed over time
The total liabilities has surged by 98% year-on-year and by 11% since the previous quarter
PCVX's quick ratio has dropped by 58% year-on-year and by 5% since the previous quarter
The debt is 96% smaller than the equity
The company's debt to equity rose by 33% YoY
The debt is up by 33% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.